Esmark’s Second Donation of $25,000 to Aid Ukrainian Refugees Fleeing to Slovakia Brings Contribution Total to $50,000; Company Rallies Nearly $12,000 in Additional Support
11.4.2022 14:45:00 EEST | Business Wire | Press release
Esmark Inc. today announced that Chairman & CEO James P. Bouchard and long-time friend Martina Roda have made a second donation of $25,000 USD to aid and support Ukrainians seeking refuge in Košice, Slovakia. This is the Company’s second donation to City of Košice, a city led by Mayor Ing. Jaroslav Polaček, to aid Ukrainians fleeing to Slovakia.
As of April 5, more than 302,700 Ukrainian refugees have entered Slovakia, according to a verified operational data portal.
The Company’s donations to the relief efforts now total $50,000 USD. In March, Esmark announced an initial donation of $25,000 USD and—in an effort to mobilize others to help—offered to match donations up to an additional $25,000 USD. To date, Esmark was directly notified of nearly $12,000 USD in donations made by Americans to support Ukrainian refugees.
Bouchard is a former U.S. Steel executive vice president and statutory representative of the Slovak Republic, transforming East Slovakian Ironworks, Košice–now known as U.S. Steel Košice–in Slovakia after U.S. Steel acquired it. Bouchard and Roda’s donations totaling $50,000 were made on behalf of the former U.S. Steel American and Slovak Commercial teams.
“While we are proud and grateful for the nearly $12,000 in donations made by Esmark friends, we couldn’t wait another moment to provide additional monetary support to the city Košice,” said Bouchard. “We are working directly with the Mayor’s office which ensures our funds are delivered immediately, enabling them to take swift action and help these refugees with humanitarian support.”
The funds from the initial donation were used to:
- Rent an agency as organizational and technical support in the center for Ukrainian refugees;
- Provide provisions and organization of Slovakian volunteers; and
- Coordinate temporary accommodation and provide provisions to Ukrainian refugees.
“The initial $25,000 from Jim and Martina enabled us to mobilize and organize more quickly,” said Košice City Mayor Ing. Jaroslav Polaček. “We are very grateful for the additional $25,000 of support, which we will focus mainly on providing transportation, accommodation and food especially for families with young children. “
“We cannot standby as we hear the first-hand accounts from our friends on the ground in Slovakia and continue to watch these events unfold on the news,” said Roda. ”We commend the Mayor, volunteers and all people of Košice who are providing much needed humanitarian support to their Ukrainian neighbors.”
Esmark and Bouchard have a history of and commitment to helping others in need. Over the last 15 years, more than $10 million has been donated to humanitarian relief and children’s charities.
About Esmark, Inc.
Esmark, Inc. is a diversified, privately-held family company with a portfolio of industrial companies with strong roots in the steel industry. Over the years, Esmark has diversified its interests and operations into a number of businesses engaged in the industrial and commodity sectors. Esmark (a former publicly traded company on NASDAQ: ESMK) has focused on several key industries including steel services, oil and gas exploration, aviation, real estate, professional services, technology and youth sports development. The company is also an active corporate citizen in the communities it serves, having committed more than $10 million in philanthropic support of a wide range of humanitarian, education, family wellness and youth sports programs in Pennsylvania, Illinois and internationally. www.esmark.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220411005180/en/
Contact information
Katie Regan
Director of Communications
Esmark, Inc.
Katie.regan@esmark.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
